Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

41.11 +2.86 (+7.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Unveiling 18 Analyst Insights On Moderna
Via Benzinga
The Bull's Biggest Hits And Misses
The bull market turned two years old over the weekend. Here are some of the S&P 500's biggest winners and losers over the last two years. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
(MRNA) - Analyzing Moderna's Short Interest
Via Benzinga
Abbas Hussain Joins Moderna's Board of Directors
Via ACCESSWIRE
Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today
Via Benzinga
2 Biotech Stocks That Are Screaming Buys This Month
They won't remain southbound forever. 
Via The Motley Fool
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
On Thursday Oct 10, 2024 Cathie Wood-Led Ark Invest sold over $9 million worth of Moderna stock. 
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga
MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
Could rebounds be in store for these beaten-down stocks? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
Exposures COVID-19
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Via ACCESSWIRE
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks might look like bad picks. But appearances can be deceiving. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Top 3 Health Care Stocks That May Explode This Month
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.